Novo Nordisk: The Thesis Is Working, The Stock Just Hasn't Noticed Yet
· seekingalpha.com
Analyst maintains a Strong Buy rating on Novo Nordisk at 10.89x non-GAAP earnings as free cash flow guidance rises to DKK 60–70 billion.
It has been nearly 3 months since I last covered a long-time holding of mine, Novo Nordisk ( NVO ), as last time I kept my Strong Buy rating following the Q2
A...